SCHEMBL29973441

SCHEMBL29973441

CC(C)(C)NS(=O)(=O)c1cccc(N)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.69
KDM4E B2RXH2 1/20 0.69
MEN1 O00255 1/20 0.69
NPC1 O15118 1/20 0.69
MAPT P10636 1/20 0.69
HPGD P15428 1/20 0.69
RAB9A P51151 1/20 0.69
KMT2A Q03164 1/20 0.69
SMN1; SMN2 Q16637 1/20 0.69
CYP19A1 P11511 1/20 0.57
POLB P06746 1/20 0.56
CA2 P00918 2/20 0.54
CA12 O43570 1/20 0.53
CA1 P00915 1/20 0.53
CA4 P22748 1/20 0.53
CA9 Q16790 1/20 0.53
CA14 Q9ULX7 1/20 0.53
F2 P00734 3/20 0.53
PRSS1 P07477 3/20 0.53
PRSS2 P07478 3/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2018411 1.00 LMNA (0.69) LMNAKDM4EMEN1NPC1MAPT
SCHEMBL5032675 0.82 ALDH1A1 (0.53) LMNAKDM4EMEN1NPC1MAPT
SCHEMBL5032618 0.82 F2 (0.50) LMNAKDM4EMEN1NPC1MAPT
SCHEMBL7141554 0.82 MAPT (0.74) LMNAKDM4EMEN1NPC1MAPT
SCHEMBL10016535 0.81 SMN1; SMN2 (1.00) LMNAKDM4EMEN1NPC1MAPT
SCHEMBL23345426 0.80 KMT2A (0.77) LMNAKDM4EMEN1NPC1MAPT
SCHEMBL7145890 0.80 LMNA (0.77) LMNAKDM4EMEN1NPC1MAPT
SCHEMBL12093538 0.80 KMT2A (0.71) LMNAKDM4EMEN1NPC1MAPT
SCHEMBL687474 0.79 LMNA (0.61) LMNAKMT2ASMN1; SMN2CYP19A1POLB
SCHEMBL11209446 0.79 LMNA (0.65) LMNAKDM4EMEN1NPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4673149-A1 NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA Trustlife Global Inc. (US) 2026-01-07 EP disclosed
US-20250188041-A1 NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA Trustlife Global Inc. 2025-06-12 US disclosed
EP-4486348-A1 NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA Trustlife Global Inc. (US) 2025-01-08 EP disclosed
CN-118804751-A New compounds and treatment of renal cell carcinoma 巴什生物技术公司 2024-10-18 CN disclosed
WO-2024179699-A1 NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA BASH BIOTECH INC. (US) 2024-09-06 WO disclosed
WO-2023166153-A1 NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA BASH BIOTECH INC (US) 2023-09-07 WO disclosed
CN-115315423-A Substituted aryl compounds 先声药业有限公司 2022-11-08 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250188041-A1 NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA RCC2, GLS, VHL LMNA 1397/4885KDM4E 2900/4885MEN1 294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.